A share price of Larimar Therapeutics Inc [LRMR] is currently trading at $3.84, down -3.27%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LRMR shares have gain 7.26% over the last week, with a monthly amount drifted -1.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Larimar Therapeutics Inc [NASDAQ: LRMR] stock has seen the most recent analyst activity on January 29, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $18. Previously, Oppenheimer started tracking the stock with Outperform rating on October 16, 2024, and set its price target to $26. On October 03, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $22 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $15 on October 02, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $16 as its price target on September 04, 2024. Leerink Partners started tracking with a Outperform rating for this stock on April 03, 2024, and assigned it a price target of $25. In a note dated November 17, 2023, Citigroup upgraded an Buy rating on this stock but restated the target price of $4.50.
Larimar Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.01 and $13.68. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Larimar Therapeutics Inc [NASDAQ: LRMR] shares were valued at $3.84 at the most recent close of the market. An investor can expect a potential return of 342.71% based on the average LRMR price forecast.
Analyzing the LRMR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.36 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.69 points at the first support level, and at 3.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.11, and for the 2nd resistance point, it is at 4.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Larimar Therapeutics Inc [NASDAQ:LRMR] is 13.10. Further, the Quick Ratio stands at 13.10, while the Cash Ratio is 2.15.
Transactions by insiders
Recent insider trading involved Hamilton Thomas Edward, Director, that happened on Feb 16 ’24 when 57208.0 shares were purchased. Director, Flynn James E completed a deal on Feb 16 ’24 to buy 4.29 million shares. Meanwhile, Director THOMAS FRANK E bought 2000.0 shares on Feb 14 ’24.
